Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tidutamab · XMAB-18087

Bispecific antibody · Immune activation, directed at CD3 (CD3E) and somatostatin receptor 2 (SSTR2) · developed by Xencor

Phase 1/2 Most advanced trial (none active)
XNCR Developer
1 Registered trials

What is Tidutamab?

Tidutamab is a humanized, Fc domain-containing bispecific monoclonal antibody that binds CD3 on T cells and somatostatin receptor 2 (SSTR2) on cancer cells. Cross-linking the two may trigger a cytotoxic T-lymphocyte response against SSTR2-expressing cells. It is being studied in Merkel cell carcinoma and small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XMAB-18087
Drug type
Bispecific antibody
Targets
CD3 (CD3E), somatostatin receptor 2 (SSTR2)
Mechanism
Immune activation, directed at CD3 (CD3E) and somatostatin receptor 2 (SSTR2)
Pathways
cytotoxic T-lymphocyte response
Therapy area
Oncology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
88635FW2QX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04590781 Phase 1/2 Merkel Cell Carcinoma Terminated XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Merkel Cell CarcinomaSmall Cell Lung Cancer

Other drugs acting on CD3E / SSTR2

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind Tidutamab

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.